Symbio Holdings LLC has been named a finalist in the TechConnect World Bio in Space Challenge, recognizing emerging technologies advancing biological research in microgravity and extreme environments.
Symbio Holdings LLC has been named a finalist in the TechConnect World Bio in Space Challenge, recognizing emerging technologies advancing biological research in microgravity and extreme environments.
Symbio’s core platform, ScenarioLab, integrates multi-agent orchestration, physics-based modeling, and reduced-order computational techniques to simulate and stress-test biological systems under constrained conditions. The platform enables rapid hypothesis exploration and digital validation before scarce physical experiments are deployed, a critical capability for space-based biomedical research.
“Our focus is on making uncertainty navigable,” said Eric McDavid, Founder of Symbio Holdings. “In space biology, physical iteration is expensive and limited. High-fidelity computational modeling can materially compress discovery cycles and improve mission readiness.”
The Bio in Space Challenge highlights innovations that accelerate translational science beyond Earth. Symbio’s selection underscores the growing role of advanced simulation and intelligent orchestration systems in aerospace and biomedical research.